Research programme: dendroaspin - Trigen

Drug Profile

Research programme: dendroaspin - Trigen

Alternative Names: Dendroaspin research programme - Trigen; ND 9

Latest Information Update: 31 Oct 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trigen Holdings AG
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 20 Oct 2005 Discontinued - Preclinical for Thrombosis in United Kingdom (unspecified route)
  • 31 May 2005 ProCorde has merged with Trigen Ltd to form Trigen Holdings AG
  • 12 May 2003 Preclinical trials in Thrombosis in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top